Boston Scientific has agreed to buy thrombectomy company Penumbra for about $15 billion in cash and stock in a deal that bolsters its cardiovascular portfolio.
Read More from WSJ.com: US Business
Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock
